問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Recruiting

List

534Cases

2020-08-01 - 2021-08-19

Phase III

A Phase III, Prospective, Multi-center, Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of Pitavastatin 2 mg/ Ezetimibe 10 mg with Pitavastatin and Ezetimibe in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

  • Condition/Disease

    Primary Hypercholesterolemia/Mixed Dyslipidemias

  • Test Drug

    1PC111

Participate Sites
23Sites

Not yet recruiting4Sites

Recruiting19Sites

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites

2014-07-15 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

  • Condition/Disease

    NA

  • Test Drug

    ARN-509; softgel capsule

Participate Sites
5Sites

Recruiting5Sites

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

1 50 51 52 53 54
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB